HDAC inhibitors such as panobinostat (Pb), vorinostat (Vr), and romidepsin (Ro) have been used in glioma models targeting the Warburg effect, disrupting super-enhancers like c-Myc itself. Here, MYC is linked to central nervous system cancer.